IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced that it is exploring a variety of strategic alternatives. The Company further stated that as part of the process the Board of Directors has formed a committee, which has retained Foros Securities LLC as its financial advisor. The Company has retained Deutsche Bank Securities Inc. as its financial advisor.
There can be no assurance that the exploration of strategic alternatives will result in a transaction. The Company does not expect to make further public comment regarding these matters while its exploration process continues.
New center established to bridge AI technology and healthcare applications